V8 Peptides — Engineered Performance
Research Library
CJC-1295 Ipamorelin Blend: Lab Planning Guide
CJC-1295 & IpamorelinStacks

CJC-1295 Ipamorelin Blend: Lab Planning Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is the CJC-1295 ipamorelin blend and how is a study built around it? It is a single co-lyophilized vial holding CJC-1295 without DAC (a GHRH-receptor analog) and ipamorelin (a ghrelin-receptor agonist) at a 1:1 mass ratio, sold for laboratory research use only. Because the two peptides act on different receptors of the same pituitary cell type, a fixed-ratio vial suits questions about combined GHRH-plus-secretagogue signaling. It cannot separate the contribution of each peptide, so a planned study needs single-peptide control arms, a vehicle control, a defined sampling schedule and a written record of vial size, lot, solvent and storage. Concentration arithmetic is mass divided by volume; the calculator does the sums.

A blend vial is a convenience and a constraint at the same time. It removes one preparation step, and it fixes the ratio of two active ingredients before the experiment begins. This guide is written for the planning stage: before a vial is opened, what question is the study asking, what comparison arms does it need, and what has to be written down so the result can be interpreted months later? It supplements the blend explainer and the CJC-1295 and ipamorelin overview instead of repeating them. Supplied for laboratory research use only; not for human consumption.

What the blend vial contains

The CJC-1295 (No DAC) + Ipamorelin blend page describes one co-lyophilized vial with the two peptides at equal mass, offered as 5 mg of each (10 mg total) or 10 mg of each (20 mg total). Purity is stated as ≥98% by HPLC, the supplied form is lyophilized powder in a sealed clear glass vial, and storage is 2–8 °C with −20 °C for long-term holding, protected from heat, moisture and light. Sequence identity is reported on the certificate of analysis where one is published in the COA library.

FeatureCJC-1295 (no DAC)Ipamorelin
Class29-residue GHRH analog (modified GRF 1-29)Synthetic pentapeptide GH secretagogue
ReceptorGHRH receptor, a Gs-coupled class B receptorGhrelin receptor (GHS-R1a)
Formula (from product pages)C152H252N44O42, about 3,368 g/molC38H49N9O5, about 712 g/mol
Residues of noteD-Ala at position 2, Gln at 8, Ala at 15Aib-His-D-2-Nal-D-Phe-Lys-NH2
Activity window in modelsShort and pulse-like because no albumin-binding group is presentShort-acting secretagogue

The ratio is by mass, not by moles. Ipamorelin is roughly a fifth of the mass of CJC-1295 per molecule, so a vial that is 1:1 by mass contains several times more ipamorelin molecules than CJC-1295 molecules. That number matters for any design that thinks in receptor occupancy. The molar arithmetic is simply mass divided by molar mass for each peptide.

The scientific logic: two receptors on one cell type

Somatotroph cells of the anterior pituitary carry both the GHRH receptor and the ghrelin receptor. The GHRH receptor was cloned as a pituitary-specific receptor in 1992 (Mayo, 1992), and the ghrelin receptor was identified in 1996 as a receptor in pituitary and hypothalamus that functions in growth hormone release (Howard and colleagues, 1996), with ghrelin later identified as its natural ligand. Reviews of growth hormone neuroregulation describe the hormone as embedded in a feedback network of hypothalamic and peripheral inputs (Giustina and Veldhuis, 1998).

That architecture is why people put the two peptides in one experiment. A GHRH analog tests the GHRH arm of the circuitry; a secretagogue tests the ghrelin arm; the two together ask whether the cell, the tissue or the animal responds to both at once differently from either alone. It is a question about interaction. A blend vial answers it only if the study is designed so that the single-peptide responses are also known.

Which questions a fixed-ratio blend can and cannot answer

A useful planning habit is to write the question as a sentence before choosing the material. The table sorts typical questions by what the blend can support.

Study questionBlend alone sufficient?What else is needed
Does a GHRH-analog-plus-secretagogue mix produce a measurable response in my somatotroph model?Yes, as a descriptive resultVehicle control and a positive-control agonist
Is the combined response larger than the sum of single responses?NoSeparate CJC-1295 and ipamorelin arms at matched concentrations
Which receptor carries the response?NoReceptor antagonists or knockdown, plus single-peptide arms
How does the response change if the ratio changes?No: the ratio is fixedIndividually prepared stocks mixed at several ratios
Is the vial consistent from preparation to preparation?YesRepeated preparations with the same recorded method

The comparison between buying the two peptides together or apart is covered from the supply side in blend versus separate vials. The point here is narrower: the blend is the right tool for the first, last and fifth rows, and the wrong one for the others. A project whose central claim is about interaction or about ratio dependence needs separate stocks, whatever the convenience of one vial.

Control arms to build in from the start

Experimental-design guidance for laboratory animals emphasizes that the structure of an experiment (the units, the controls, the randomization) determines what can be concluded, not the statistics applied afterwards (Festing and Altman, 2002). The same holds for cell work. A blend experiment normally needs the following arms.

  • Vehicle control. The exact diluent used for the vial, including any preservative, carried through the same dilutions and handling. Benzyl alcohol, if present in the diluent, is an assay variable of its own.
  • CJC-1295 alone. Prepared from a separate single-peptide vial at the same mass or molar concentration as in the blend, so that the contribution of the GHRH arm is known.
  • Ipamorelin alone. The ipamorelin product page lists a single-peptide vial for this purpose.
  • Positive control. A reference agonist for each receptor in the model, to confirm that the cells or tissue are responsive on the day.
  • Antagonist or pathway-blocking arm where the question is about mechanism.

Decide at the outset whether concentrations are matched by mass or by moles. By mass the two peptides share the same numbers; by moles they do not. Whichever is chosen, say so in the methods, because a reader who assumes the other convention will misread the result.

Readouts and sampling: matching the endpoint to the model

The response of a pulsatile system depends on when it is sampled. In vivo models of the axis show ultradian growth hormone rhythms produced by the reciprocal action of GHRH and somatostatin (Tannenbaum and Ling, 1984), and detecting pulses in a time series takes defined algorithms rather than eyeballing (Veldhuis and Johnson, 1986). In cell and tissue systems the readouts are different but the timing logic is the same.

ModelTypical readoutSampling consideration
Dispersed pituitary cells or cell lines expressing the receptorscAMP accumulation, calcium signal, hormone released into mediumEarly time points for second messengers; later for secreted hormone
Perifused pituitary fragmentsHormone release profile over timeContinuous collection allows pulse-shaped analysis
Rodent models in published workPlasma GH profile; IGF-I as a slower, integrating markerFrequent short-interval sampling for pulses; single time points for IGF-I

If IGF-I is measured, remember it integrates secretion over hours to days and lags the pituitary signal, so it answers a different question than a minute-scale GH time course. Writing the timing of each draw or collection into the protocol before starting protects against the common error of choosing the sampling window after seeing early results.

Preparing the vial: the short version

Handling detail belongs in a dedicated guide, and the blend reconstitution and storage guide and how to reconstitute a lyophilized peptide cover it. For planning purposes four rules are enough. Let the sealed vial reach room temperature before opening. Add diluent slowly against the glass wall and swirl rather than shake. Compute concentration from the labeled mass and the volume actually added, using a formula and not a remembered figure. Write the result down.

The formula is concentration of each peptide = mass of that peptide in the vial ÷ volume of diluent added. Total peptide concentration is the sum of the two. Because the vial is 1:1 by mass, each peptide has the same mass concentration and the total is double it. Convert to molar by dividing the mass concentration by the molar mass of the peptide. The reconstitution calculator handles the mass-per-volume step and reconstitution volume calculations shows the working.

Documentation checklist for a blend study

Write the following on the first page of the notebook entry for a blend experiment.

  • Vial size (5 mg / 5 mg or 10 mg / 10 mg), lot number and the COA reference where one is listed.
  • Diluent type, lot and volume added; date and time of reconstitution; operator.
  • Concentration of each peptide, calculated with the formula, including whether it is stated by mass or by moles.
  • Storage temperature after reconstitution, number of times the stopper was pierced, and the number of freeze–thaw cycles, which should be zero or one for a given aliquot.
  • Appearance on preparation and at each use. A clear, colorless solution is expected; see what a normal peptide vial looks like and cloudy peptide vial after reconstitution.
  • The identity of the single-peptide control vials and their own lots.

The point of the list is not bureaucracy. When a result looks surprising, the first thing to check is whether the material behaved as intended, and only a record made at the time can answer that. The guide to reading a COA explains the analytical fields the lot reference points to.

Limits of the published evidence

The two components have separate, well-defined literatures. CJC-1295 in its albumin-binding form is described in rats (Jetté and colleagues, 2005); ipamorelin was characterized as a selective secretagogue in rat and swine models (Raun and colleagues, 1998). The no-DAC compound sold here has the older modified GRF(1-29) lineage and the pillar article on the CJC-1295 No DAC research overview traces it. A study of the combination in a particular model may not have a precedent, which is a reason to build the single-peptide arms rather than assume one. Nothing in this guide is a statement about use outside the laboratory.

The related pages on CJC-1295 versus ipamorelin, ipamorelin and the single-peptide CJC-1295 (No DAC) product give the component-level background.

Frequently asked questions

What is in the CJC-1295 ipamorelin blend vial?

Two peptides co-lyophilized at a 1:1 mass ratio: CJC-1295 without DAC (modified GRF 1-29) and ipamorelin. It is offered as 5 mg + 5 mg or 10 mg + 10 mg, as lyophilized powder with a stated purity of ≥98% by HPLC, for laboratory research use only.

Is the blend 1:1 by mass or by moles?

By mass. Because ipamorelin is a much smaller molecule than CJC-1295, equal mass means more ipamorelin molecules than CJC-1295 molecules. Convert mass concentration to molar concentration with each peptide’s molar mass if a design is molar.

Can a blend vial show whether the two peptides interact?

Not alone. Showing interaction requires single-peptide arms at matched concentrations so the combined response can be compared with the individual ones.

What control arms does a blend experiment need?

A vehicle control using the same diluent, a CJC-1295-only arm, an ipamorelin-only arm, a positive control for each receptor, and a blocking arm if the question is mechanistic.

Why do the two peptides appear together in research?

Both act on pituitary somatotrophs through different receptors, the GHRH receptor and the ghrelin receptor. Studying them together allows questions about combined signaling and pulsatile secretion models.

How is concentration calculated for the blend?

Concentration of each peptide equals its mass in the vial divided by the volume of diluent added. Total concentration is the sum, which is double the single value for a 1:1 vial. The reconstitution calculator performs the arithmetic.

Should IGF-I be used as a readout?

It can be used as a slower integrating marker in animal models, but it lags pituitary signaling by hours. Minute-scale GH profiles and IGF-I answer different questions, so the choice should follow the study question.

How should a reconstituted blend be stored?

Cold and protected from light, in single-use aliquots where possible, with the number of stopper punctures and freeze–thaw cycles recorded. The product page gives 2–8 °C for the sealed powder and −20 °C for long-term storage.

Does the published literature cover this exact blend?

Mostly it covers the components separately: the albumin-binding CJC-1295 form and ipamorelin in animal models. A specific combination in a specific model may have no precedent, so single-peptide controls matter.

Where can the certificate of analysis be found?

In the COA library, where one has been published for the lot. If none is listed for a lot, record that in the notebook instead of leaving the field empty.

Related reading: CJC-1295 Ipamorelin Blend Shelf Life and Stability, CJC-1295 Ipamorelin Blend or Separate Vials?, CJC-1295 + Ipamorelin: Testing Additivity and Synergy.

References

  1. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
  2. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
  3. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353
  4. Festing MFW, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244-258. doi:10.1093/ilar.43.4.244
  5. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-1957. doi:10.1210/endo-115-5-1952
  6. Veldhuis JD, Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol. 1986;250(4 Pt 1):E486-E493. doi:10.1152/ajpendo.1986.250.4.E486
  7. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  8. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.